Ashland says it will ramp up production of the tablet disintegrant and dissolution aid polyvinylpyrrolidone (PVPP) to meet growing drug industry demand.
Amarin plans to add a fourth API maker to its supply chain as it prepares for a potential launch of its triglyceride lowering therapy, AMR101, in the US in 2012.
Rousselot says its acquisition of Eastman Kodak’s Gel Corporation will boost its gelatine production capacity and help it meet soaring drug industry demand.
It’s been a busy year for API (active pharmaceutical ingredient) manufacturers with new facilities, cost pressures and regulatory developments all hitting the headlines.And it seems recent developments in HPAPIs (high potency APIs) have caused a stir...
China will keep its position as a leading API and intermediates supplier thanks to recovering global demand and the growth of the generic sector say market analysts.
BASF has raised its prices for three ethanolamines (EOA), key intermediates in the production of a wide range of active pharmaceutical ingredients (API).
Seppic has seen a boom in demand for its new natural origin coating agents for pharmaceuticals, which can speed up production time by 50 per cent at lab stage.
Chemicals firm Vertellus Specialties has begun manufacturing operations at a new facility in China, citing growth of the country’s cyanopyridines market as the key driver for the investment.
Taste masking plays a vital role in treatment compliance according to Cargill, which has launched a new flavour technology that it claims can make drugs more pleasant to take and help manufacturers save money.
High potency APIs are becoming a key focus of the pharmaceutical business, with drug makers from all areas racing to establish a foothold in the market.
in-PharmaTechnologist presents its round-up of the latest drug delivery research developments in the pharmaceutical world, including tumour targeting peptides and lipid nanoparticle drug-delivery technology.
GlaxoSmithKline (GSK) has urged the US FDA consider the absorption of nanomaterials in the gastrointestinal (GI) tract within its proposal for new regulations on nanotechnology.
Endeavour Specialty Chemicals has launched a novel range of pyridinyl thioureas designed to cater for growing pharmaceutical industry interest in the development of prion disease treatments.
Bristol-Myers Squibb has penned a technology transfer agreement with the Brazilian government in what it says is a bid to increase access to HIV drug Reyataz (atazanavir sulfate) in the area.
BASF will start producing synthetic menthol next year using a new method that, it claims, offers significant quality and supply advantages for drug and food manufacturers.
